Serum testosterone and prostate-specific antigen levels are major risk factors for prostatic volume increase among benign prostatic hyperplasia patients

Gede Wirya Kusuma Duarsa a,*, Yudit Anastasia Sari b, Anak Agung Gde Oka a, Kadek Budi Santosa a, I Wayan Yudiana a, Pande Made Wisnu Tirtayasa a, Ida Bagus Putra Pramana a, Yudhistira Pradnyan Kloping c

a Department of Urology, Sanglah General Hospital, Faculty of Medical and Health Sciences of Udayana University, Denpasar, Bali, Indonesia
b General Surgery Department, Faculty of Medicine Udayana University, Denpasar, Bali, Indonesia
c Medical Faculty, Universitas Airlangga, Surabaya, East Java, Indonesia

Received 18 January 2020; received in revised form 9 March 2020; accepted 22 April 2020
Available online 7 June 2020

Keywords
Testosterone; Prostate-specific antigen; Prostate volume; Benign prostatic hyperplasia

Abstract Objective: Benign prostatic hyperplasia (BPH) is one of the most common diseases found among elderly men. Even though multiple risk factors of BPH have been identified in the past, the risk factors which have a direct impact on prostate volume have not been identified. In this study, we aim to determine the most significant contributing risk factors to prostate volume enlargement by analyzing possible associated risk factors previously studied.

Methods: This is a quantitative study with an analytical observational design, performed using a retrospective cohort approach. Total sampling was performed on 83 patients who underwent transurethral resection of the prostate (TURP) in Sanglah General Hospital from January to February 2019. Bivariate analysis is performed to examine each variable’s association with prostate volume followed by a multivariate analysis. All variables were reassessed with path analysis to measure the direct effects, indirect effects, and total effects on prostate volume.

Results: Bivariate analysis shows that serum testosterone (R=0.208; p=0.059) and prostate-specific antigen (PSA) level (R=0.626; p=0.001) have a significant association with prostate volume. Multivariate analysis shows that serum PSA (B=1.4; p=0.001; 95% confidence interval [95% CI]=1.039–1.770) and testosterone (B=0.024; p=0.005; 95% CI=0.008–0.041) levels are significant among all the analyzed risk factors. There is a significant and strong effect of PSA to...
1. Introduction

Interest and focus of urologists have never shifted far from benign prostatic hyperplasia (BPH) as it is one of the most common diseases found among elderly men [1]. Multiple studies worldwide have shown that the prevalence of the disease is at an all-time high especially among people above the age of 60. It is estimated that almost 70 percent of United States men between the age of 60 and 69 years have a certain degree of BPH [2]. Unfortunately, the prevalence rate of BPH in Indonesia has never been studied or published [3]. In Sanglah General Hospital, Bali alone there are 103 BPH patients who underwent transurethral resection of the prostate (TURP) in 2013 [4]. Even though it has been one of the main protagonist of urologic diseases for years, studies focusing on its associated risk factors are still being performed to this day. Latest findings claimed that BPH is no longer considered as a single disease but a manifestation caused by systemic alterations induced by multiple risk factors [5]. Multiple risk factors for BPH have been identified in the past. However, the risk factors which have a direct impact on prostate volume have yet to be identified. As severity progression based on the lower urinary tract symptoms (LUTS) of the disease is closely associated with the increase of prostate volume, it is necessary to identify these factors to evaluate new prevention strategies in the future. Therefore, in this study we aim to determine the most significant contributing risk factors to prostate volume enlargement by analysing the possible associated risk factors previously studied: Age, urinary tract infection, type 2 diabetes mellitus (T2DM), obesity, dyslipidemia, serum testosterone level, prostate-specific antigen (PSA) level, tumor necrosis factor (TNF)-α and TGF-β levels in prostate tissue.

2. Methods

2.1. Study population

This study is a quantitative study with an analytical observational design, performed using a retrospective cohort approach. Total sampling was chosen as the sampling method analysing 83 patients who underwent TURP in Sanglah General Hospital from January 2018 to February 2019. The inclusion criteria of this study are: Male patients around the age of 50–80 years old, prostate volume ranging from 20 to 80 mL, and have undergone TURP with a histopathology result confirming the diagnosis of BPH. Patients with confirmed infection, uncontrolled diabetes mellitus, existing bladder stone with length or width longer than 2.5 cm, confirmed bladder tumor, urinary catheter use for more than 1 year, and patients who routinely consumed nonsteroidal anti-inflammatory drugs (NSAID) or aspirin are excluded.

2.2. Study variables

Independent variables included in this study consist of patients’ age, body mass index (BMI), fasting plasma glucose level, plasma glucose level 2 h post prandial, testosterone level, PSA level, total cholesterol level, triglyceride level, urine culture results, prostate volume, TNF-α and TGF-β level. Prostate volume is assigned as the dependent variable.

2.3. Statistical analysis

Bivariate analysis is performed to examine each variable’s association with prostate volume followed by a multivariate analysis using the logistic regression method. All variables were reassessed with path analysis to measure direct effects, indirect effects, and total effects from each significant risk factor regarding prostate volume. The statistical analysis is performed using IBM SPSS® 23.0 (International Business Machines [IBM] Corporation, New York, USA). The path analysis is performed using IBM SPSS® AMOS.

3. Results

3.1. Subjects’ characteristics

Out of the 103 patients who underwent TURP, 83 patients fit the study inclusion criteria. The subjects’ variables and characteristics are presented in Table 1.

3.2. Bivariate analysis

Bivariate analysis is performed to evaluate any associations between the risk factors and prostate volume using the Spearman method based on the statistical scale of the data. Both serum testosterone (R = 0.208; p = 0.059) and PSA level (R = 0.626; p = 0.001) have a significant association with prostate volume as shown in Table 2.

3.3. Linear regression analysis

Multivariate analysis is performed using the linear regression method to obtain the most significant risk factors.
The characteristics data collected from the patients were prostate volume assigned as the dependent variable for PSA. Analyzing the direct effect of risk factors to PSA, there is no direct effect from other risk factors to serum testosterone levels as shown in Table 5. There is no direct effect from other risk factors to serum testosterone levels as shown in Table 5.

### 3.4. Path analysis

A path analysis of the variables is performed to examine the dependencies among the risk factors and their relationships to prostate volume.

#### 3.4.1. Two-sided correlation between risk factors

In Table 4, the two significant correlations of risk factors are the correlation between T2DM and obesity ($r = 0.191; p = 0.005$; $95\% \text{ CI} = 0.057–0.325$), between diabetes mellitus type 2 and dyslipidemia ($r = 0.323; p = 0.001$; $95\% \text{ CI} = 0.155–0.490$) and between TNF-$\alpha$ and TGF-$\beta$ levels ($r = 0.515; p < 0.001$; $95\% \text{ CI} = 0.352–0.678$).

#### 3.4.2. One-sided correlation between risk factors and prostate volume

In Table 4, the one side correlation analysis between risk factors and prostate volume, shows that T2DM has a negative correlation with prostate volume ($r = -0.227; p = 0.001$; $95\% \text{ CI} = -0.360–0.094$). PSA, on the other hand, has a one-way correlation with prostate volume ($r = 0.636; p = 0.001$; $95\% \text{ CI} = 0.471–0.802$). Testosterone also has a weak one side correlation with prostate volume, albeit weak ($r = 0.246; p = 0.013$; $95\% \text{ CI} = 0.051–0.440$).

#### 3.4.3. Direct effect of risk factors to PSA

Analyzing the direct effect of risk factors to PSA, Table 5 shows T2DM has a negative direct effect with PSA ($r = -0.061; p = 0.003$), whereas other risk factors do not have a significant direct effect to PSA. This indicates that the presence of T2DM lowers the increase of PSA.

#### 3.4.4. Direct effect of risk factors to testosterone

There is no direct effect from other risk factors to serum testosterone levels as shown in Table 5.

#### 3.4.5. Direct effect of risk factors to prostate volume

In Table 5, showing the direct effect of risk factors to prostate volume, PSA has a relatively strong direct effect on prostate volume ($r = 0.636; p = 0.001$), whereas serum testosterone has a weak effect to prostate volume ($r = 0.246; p = 0.009$).

#### 3.4.6. Indirect effect of risk factors to prostate volume

T2DM has a negative indirect effect with prostate volume ($r = -0.187; p = 0.005$) due to its negative association with PSA.

#### 3.4.7. Total effect of risk factors to prostate volume

There are significant and strong effects of PSA on prostate volume ($c = 0.636; p = 0.001$) whereas testosterone has a significant albeit weak effect to prostate volume ($c = 0.246; p = 0.009$) based on the total effect shown in Table 6.

### Table 1: Subjects’ characteristics.

| Variable                  | Mean $\pm$ SD or n (%) | $p$-Value |
|---------------------------|------------------------|-----------|
| Age (year)$^{a}$          | 64.4 $\pm$ 8.2         | 0.181     |
| Body mass index (kg/m$^2$)$^{a}$ | 23 $\pm$ 3.3        | 0.200     |
| Fasting plasma glucose    | 103.2 $\pm$ 30.2       | $<0.001$  |
| (mg/dL)$^{a}$             |                        |           |
| Plasma glucose 2 h post   | 131.8 $\pm$ 45.4       | $<0.001$  |
| prandial (mg/dL)$^{a}$    |                        |           |
| Total cholesterol (mg/dL)$^{a}$ | 166.4 $\pm$ 41.7     | 0.200     |
| Triglyceride (mg/dL)$^{a}$ | 144.2 $\pm$ 214.8     | $<0.001$  |
| PSA (ng/mL)$^{a}$         | 8.1 $\pm$ 8.1         | 0.001     |
| Testosterone (ng/ml)$^{a}$ | 412.4 $\pm$ 177       | 0.200     |
| TNF-$\alpha$ (pg/mg)$^{a}$ | 50.8 $\pm$ 22.9      | $<0.001$  |
| TGF-$\beta$ (pg/mg)$^{a}$ | 221.1 $\pm$ 22.9      | $<0.001$  |
| Urine culture result      |                        |           |
| Negative                  | 71 (85.5)              |           |
| Positive                  | 12 (14.5)              |           |
| Prostate volume (mL)$^{b}$ | 46.3 $\pm$ 7.8        | $<0.001$  |

SD, standard deviation; TGF, transforming growth factor; TNF, tumor necrosis factor; PSA, prostate-specific antigen.

$^{a}$ The characteristics data collected from the patients were assigned as independent variables for the analysis.

$^{b}$ Prostate volume was assigned as the dependent variable for the analysis.

### Table 2: Bivariate analysis results between risk factors and prostate volume.

| Risk factor                  | Prostate volume | r-score | $p$-Value |
|------------------------------|-----------------|---------|-----------|
| Age (year)                   | 0.098           | 0.377   |
| Body mass index (kg/m$^2$)   | 0.007           | 0.953   |
| Fasting plasma glucose (mg/dL)| -0.201          | 0.068   |
| Plasma glucose 2 h post prandial (mg/dL) | -0.147        | 0.186   |
| Total cholesterol (mg/dL)    | 0.111           | 0.922   |
| Triglyceride (mg/dL)         | 0.002           | 0.986   |
| PSA (ng/mL)                  | 0.626           | 0.001   |
| Testosterone (ng/mL)         | 0.208           | 0.059   |
| TNF-$\alpha$ (pg/mg)        | -0.089          | 0.423   |
| TGF-$\beta$ (pg/mg)         | 0.000           | 0.998   |
| Urine culture results        | -0.117          | 0.294   |

PSA, prostate-specific antigen; TNF, tumor necrosis factor; TGF, transforming growth factor.

*Biivariate analysis is performed using the spearman method based on the variables’ data scale to evaluate the relationship between each variable and prostate volume.

### Table 3: Linear regression results of risk factors regarding prostate volume.

| Variable              | B    | 95% CI             | $p$-Value | $R^2$ |
|-----------------------|------|--------------------|-----------|-------|
| PSA                   | 1.4  | 1.039–1.770        | 0.001     | 44.3% |
| Testosterone          | 0.024| 0.008–0.041        | 0.005     |       |

*Linear regression method performed to assess the most significant variables among the risk factors.

PSA, prostate-specific antigen; CI, confidence interval.
Path analysis (illustration shown in Fig. 1) exhibiting the correlation between variables not previously discovered.

### Table 4  Correlation between two risk factor variables.

| Correlation | r-score | p-Value | 95% CI |
|-------------|---------|---------|--------|
| Age ↔ UTI   | 0.076   | 0.511   | 0.303–0.151 |
| Age ↔ T2DM  | 0.157   | 0.114   | 0.351–0.038 |
| Age ↔ Obesity | 0.187 | 0.094   | 0.407–0.032 |
| Age ↔ Dyslipidemia | -0.123 | 0.311   | -0.362–0.115 |
| Age ↔ TNF   | 0.021   | 0.862   | 0.235–0.213 |
| Age ↔ TGF   | 0.023   | 0.818   | 0.174–0.221 |
| UTI ↔ T2DM  | -0.086  | 0.368   | -0.274–0.101 |
| UTI ↔ Obesity | -0.018 | 0.861   | -0.224–0.187 |
| UTI ↔ Dyslipidemia | -0.033 | 0.745   | -0.229–0.163 |
| UTI ↔ TNF   | 0.174   | 0.182   | -0.081–0.429 |
| UTI ↔ TGF   | 0.003   | 0.972   | -0.184–0.190 |
| T2DM ↔ Obesity | 0.191  | 0.005   | 0.057–0.325 |
| T2DM ↔ Dyslipidemia | 0.323<0.001 | 0.155–0.490 |
| T2DM ↔ TNF   | -0.085  | 0.395   | -0.279–0.110 |
| T2DM ↔ TGF   | -0.127  | 0.066   | -0.262–0.008 |
| Obesity ↔ Dyslipidemia | 0.071  | 0.504   | 0.138–0.281 |
| Obesity ↔ TNF | -0.182  | 0.167   | -0.440–0.076 |
| Obesity ↔ TGF | -0.101  | 0.361   | -0.317–0.116 |
| Dyslipidemia ↔ TNF | 0.154  | 0.121   | -0.041–0.349 |
| Dyslipidemia ↔ TGF | 0.157  | 0.108   | -0.034–0.348 |
| TNF ↔ TGF   | 0.515   | <0.001  | 0.352–0.678 |

**PSA**, prostate-specific antigen; **TNF**, tumor necrosis factor; **TGF**, transforming growth factor; **UTI**, urinary tract infection; **T2DM**, type 2 diabetes mellitus.

*Path analysis (illustration shown in Fig. 1) exhibiting the correlation between each variable to show that there may be associations between variables not previously discovered.

### 4. Discussion

Recent observational studies concluded that age is one of the risk for the onset and progression of the disease [6]. A longitudinal study in Krimmen and Baltimore claimed that prostate size grows with a rate of 2.0%–2.5% each year in elderly males [7,8]. In this study, age with a mean sample age of 64.4 years is not significantly associated with prostate volume based on the bivariate analysis (r = 0.098; p = 0.377) and the total effect analysis (r = 0.088; p = 0.379). Even though the prevalence of BPH seems to increase with age, there are other factors with higher level of association with prostate volume. On a healthy elderly male with no comorbidities, the progression of BPH may not be that severe, making the association weaker compared to other risk factors.

Bladder outlet obstruction which increases the occurrence of urinary stasis may promote bacteria to invade the urothelium causing a urinary tract infection [9]. In this study, the presence of UTI as indicated by urinary culture result is not significantly associated with prostate volume based on the bivariate analysis (r = -0.117; p = 0.294) and the total effect (r = -0.061; p = 0.588). Theoretically a large postvoid residual volume of urine caused by a chronic bladder outlet obstruction would generate a predisposition to UTI. However, currently there is only little evidence based on previous studies which claims that the occurrence of UTI is associated with diseases related to bladder outlet obstruction [10]. There may not be many significant correlation found in studies, due to multiple confounding bias surrounding the pathogenesis of UTI which can't be attributed much to urinary stasis only.

A meta-analysis study in 2012 showed a significant positive association between BMI and BPH-induced lower urinary tract symptoms (LUTS) [11]. Central obesity specifically is often present alongside BPH in multiple studies [12–15]. On the contrary, several prospective studies claimed that there is no association between obesity and LUTS in BPH patients [16,17]. The insignificant association with prostate volume in this study based on the bivariate (r = 0.007; p = 0.953) and total effect analysis (r = 0.103; p = 0.380) may be due to the averagely normal BMI among the patients and the lower than average BMI of Indonesian and Asian people compared to American or European people.

An animal model study evaluating the effects of feeding the animals with a high cholesterol diet came to a conclusion that the intervention is able to induce prostatic enlargement [18]. This finding is supported by a study showing that subjects with symptomatic BPH overall have higher low-density lipoprotein (LDL) cholesterol level and lower high-density lipoprotein (HDL) cholesterol level [19]. Oxidized LDL is believed to be able to increase secretion of growth factors and pro-inflammatory cytokines released by human stromal BPH cells where triglyceride (TG) level do...
bivariate analysis of fasting plasma glucose ($r = -0.201$; $p = 0.068$) and plasma glucose 2 h post prandial ($r = -0.147; p = 0.186$) as well as an insignificant total effect analysis of the diagnosis of T2D and prostate volume ($r = -0.193; p = 0.165$). However, T2D is indirectly related to prostate volume ($r = -0.187; p = 0.005$) albeit negatively, meaning that the presence of T2D indirectly lowers the risk of prostatic enlargement. Several studies have proposed a significant independent association of T2DM to BPH caused by mechanisms such as hyperinsulinemia and insulin growth factor (IGF) affecting the receptors in stromal and epithelial cells of prostate [23,24]. Insulin resistance is claimed to be an important factor for prostate gland enhancement by some studies [25,26]. High level of insulin may alter the metabolism of sex hormones directly or indirectly through obesity [27]. It is able to increase the amount of androgen and Estrogen affecting prostatic cells by lowering sex hormone-binding globulin levels [20]. Additionally, hyperinsulinemia is able to increase catecholamines in plasma and tissue, which further promotes hyperplasia of the cells [28]. High level of glucoses promote the level of calcium in smooth muscle cells and neural tissues, activating the sympathetic nervous system. This activation may increase the tone of prostatic smooth muscles which worsens existing symptoms [29,30]. Sarma et al. [31] performed a prospective study which showed that diabetes may be linked to LUTS.

### Table 5

| Effect | r-score | p-Value |
|--------|---------|---------|
| Direct effect to prostate volume | | |
| Prostate volume $\rightarrow$ PSA | 0.636 | <0.001 |
| Prostate volume $\rightarrow$ Testosterone | 0.246 | 0.009 |
| Prostate volume $\rightarrow$ Age | 0.036 | 0.590 |
| Prostate volume $\rightarrow$ UTI | -0.039 | 0.603 |
| Prostate volume $\rightarrow$ DM | -0.006 | 0.957 |
| Prostate volume $\rightarrow$ Obesity | 0.082 | 0.304 |
| Prostate volume $\rightarrow$ Dyslipidemia | 0.099 | 0.208 |
| Prostate volume $\rightarrow$ TNF | -0.019 | 0.852 |
| Prostate volume $\rightarrow$ TGF | 0.039 | 0.652 |

### Table 6

| Effect | Coefficient | p-Value |
|--------|--------------|---------|
| PSA $\rightarrow$ Age | 0.089 | 0.344 |
| PSA $\rightarrow$ UTI | -0.018 | 0.855 |
| PSA $\rightarrow$ T2DM | -0.227 | 0.003 |
| PSA $\rightarrow$ Obesity | -0.000 | 0.998 |
| PSA $\rightarrow$ Dyslipidemia | -0.004 | 0.968 |
| PSA $\rightarrow$ TNF | 0.051 | 0.707 |
| PSA $\rightarrow$ TGF | -0.18 | 0.888 |
| Prostate volume $\rightarrow$ PSA | 0.636 | <0.001 |
| Prostate volume $\rightarrow$ Testosterone | 0.245 | 0.009 |
| Prostate volume $\rightarrow$ Age | 0.088 | 0.379 |
| Prostate volume $\rightarrow$ UTI | -0.061 | 0.588 |
| Prostate volume $\rightarrow$ T2DM | -0.193 | 0.165 |
| Prostate volume $\rightarrow$ Obesity | 0.103 | 0.380 |
| Prostate volume $\rightarrow$ Dyslipidemia | 0.077 | 0.446 |
| Prostate volume $\rightarrow$ TNF | 0.010 | 0.942 |
| Prostate volume $\rightarrow$ TGF | 0.006 | 0.956 |
| Testosterone $\rightarrow$ Age | -0.018 | 0.881 |
| Testosterone $\rightarrow$ UTI | -0.045 | 0.734 |
| Testosterone $\rightarrow$ DM | -0.171 | 0.131 |
| Testosterone $\rightarrow$ Obesity | 0.087 | 0.399 |
| Testosterone $\rightarrow$ Dyslipidemia | -0.078 | 0.608 |
| Testosterone $\rightarrow$ TNF | -0.014 | 0.918 |
| Testosterone $\rightarrow$ TGF | -0.085 | 0.455 |

PSA, prostate-specific antigen; TNF, tumor necrosis factor; TGF, transforming growth factor; UTI, Urinary Tract infection; T2DM, type 2 diabetes mellitus.

*Path analysis (illustration shown in Fig. 1) exhibiting the total causative effect from each variable to prostate volume to show a complete cause–effect relationship.

---

not [20]. On the contrary, in this study the bivariate analysis of cholesterol ($r = 0.011; p = 0.922$) and triglyceride ($r = 0.077; p = 0.446$) as well as the total effect analysis of dyslipidemia ($r = 0.077; p = 0.446$) to prostate volume are insignificant. The results are in line with the findings from studies that fail to find the association between benign prostatic enlargement (BPE) and dyslipidemia [21,22]. This may indicate that the presence of mere dyslipidemia alone without any comorbidities as a part of metabolic syndrome is not enough to affect prostate volume.

Since 1966, researchers have already suspected a connection between BPH and metabolic abnormalities related to glucose metabolism [23]. Following the abundance of literatures evaluating the connection between T2DM and BPH, this study results in an insignificant
but not prostate volume. A study by Burke et al. [32] also failed to show the connection between T2DM and prostate volume. The association is found to be closely related to the dynamic components of urinary tract functions, but not prostate volume.

Aside from hormonal factors, inflammation is also considered to be responsible for contributing to the development of BPH. The inflammation process explained usually occurs in a systemic level associated with metabolic syndrome or locally in cases like prostatitis [33]. In some ways or another, inflammation has a role in the development of BPH shown by histological findings obtained from biopsies and surgeries [34]. Immune cells like macrophages and T-Cells produce TNF-α as an inflammatory response. The cytokine promotes interleukin-6 (IL-6) which induces proliferation of epithelial cells [35–38]. Previous study conducted by Duarsa et al. [39] in 2018 showed a significant difference of TNF-α expression in LUTS patients after being performed a TURP compared to non-LUTS patients. In this study, we examine the association of the cytokine with prostate volume resulting in a Bivariate analysis (r = -0.089; p = 0.423) and total effect analysis (r = 0.010; p = 0.942). This shows that in relation to prostate volume only, the cytokine is not significantly impactful compared to other possible risk factors. A similar result can be seen with TGF-β. The bivariate analysis (r = -0.006; p = 0.956) reveal an insignificant association. The same study conducted by Duarsa et al. [39] also evaluated the association of TGF-β which is shown to be significantly higher on BPH patients with LUTS after TURP. In the human body, TGF-β is able to induce proliferation in prostatic stromal cells, however it is also responsible in the pathway of growth arrest of the cells. TGF-β1 at low doses is able to induce proliferation with the help of platelet-derived growth factor (PDGF), however at high doses it is able to cause growth arrest of prostatic stromal cells [40]. This complex dose-dependent mechanism of the cytokine is the result of many systemic processes which cannot be attributed to one pathophysiology process. Thus, the independent association of the cytokine solely with prostate volume is difficult to be proven significant as seen in the results of the study.

Physiologically, unlike other organs the prostate keeps growing throughout the adult male life [41]. An ample amount of studies in the past have explored the role of testosterone in the increase of prostate volume. However, what’s interesting is that as age continues to increase, the hormone is actually declining resulting in a seemingly paradoxical correlation between testosterone and BPH [33]. A theory suggests that the metabolite of the hormone, dihydrotestosterone (DHT) should be taken into account as it is able to bind with androgen receptors with greater affinity compared to testosterone [42]. It is found to be responsible in initiating prostate cell’s proliferation and growth. van der Sluis and associates reported that DHT activity is highly found in prostate with BPH. In a study examining the effects of hormone replacement therapy (HRT) using testosterone, they discovered that the hormone significantly increases

![Figure 1](image-url) Risk factors for prostatic volume increase path analysis. PSA, prostate-specific antigen; TNF, tumor necrosis factor; TGF, transforming growth factor; UTI, urinary tract infection; T2DM, type 2 diabetes mellitus.
prostate volume and PSA levels [43]. Several studies have concluded the association with testosterone administration during therapy [33]. Aside from DHT, estradiol, which is also derived from testosterone is also claimed to have an independent effect on prostate volume. The risk for BPH is proven to be related to serum estradiol independently in cohort studies [44]. However its association to prostate volume alone has yet to be proven. A positive association of these metabolites’ precursors is seen in this study based on the logistic regression analysis (B = 0.024; p = 0.005) and total effect analysis (r = 0.245; p = 0.009). The results in this study evidently show that serum testosterone is significantly associated with and directly impacts the increase of prostate volume in BPH. On a different note, in its relation to prostate cancer, serum testosterone levels are usually found to be lower among prostate cancer patients with high Gleason score. Dell’Atti et al. [45] reported that serum testosterone levels change significantly on patients with a confirmed diagnosis of prostate cancer on the second biopsy who were previously found with atypical small acinar proliferation during the first biopsy performed 6 months prior. The next step following the findings of this study should focus on evaluating the serum level of DHT and estradiol among BPH patients and their association with prostate volume.

A study by Deori et al. [46] shows that 52% of male patients with PSA levels ranging between 1.1 and 1.5 ng/mL and 65% of male patients with PSA levels ranging between 1.6 and 2.0 ng/mL have prostate with a volume of more than 30 mL. They concluded that PSA serum of more than 1.5 ng/mL can be used as functional cut off point for screening male patients with prostate with a volume of more than 30 mL. PSA level could be used as estimator for prostate volume measurement according to a study conducted by Putra et al. [47]. In this study, we found that every 1 ng/mL PSA serum increase is related to an increase in prostate volume size by 1.4 mL. The bivariate analysis (r = 0.626; p = 0.001); logistic regression analysis (B = 1.4; p = 0.001), and total effect analysis (r = 0.636; p = 0.001) of PSA in association with prostate volume in this study show significant connections.

Considering the differences of results between this study and previous ones, it has become clearer that prostate volume increase in BPH results from a variety of risk factors which could occur together coactively or independently at different times. Upon examining the possible risk factors through a multivariate analysis followed by a path analysis, we have determined that as the end process of all risk factors that are related to each other, serum testosterone and PSA level are the major risk factors which are significantly associated to and directly impact prostate volume. Future studies regarding a similar topic should attempt to increase the sample size as this study was limited by its sample size.

5. Conclusion

Serum testosterone and PSA levels are significantly associated with prostatic volume increase among BPH patients.

Author contributions

Study concept and design: Gede Wirya Kusuma Duarsa, Yudit Anastasia Sari. Data acquisition: Yudit Anastasia Sari, Anak Agung Gede Oka. Data analysis: Yudit Anastasia Sari, Yudhistira Pradnyan Kloping. Investigation: Yudit Anastasia Sari, Anak Agung Gede Oka, Kadek Budi Santosa, I Wayan Yudiana, Pande Made Wisnu Tirtayasa, Ida Bagus Putra Pramana. Resources: Anak Agung Gede Oka, Kadek Budi Santosa, I Wayan Yudiana, Pande Made Wisnu Tirtayasa, Ida Bagus Putra Pramana. Drafting of manuscript: Gede Wirya Kusuma Duarsa, Yudit Anastasia Sari, Yudhistira Pradnyan Kloping. Critical revision of the manuscript: Yudit Anastasia Sari, Yudhistira Pradnyan Kloping. Project Administration: Gede Wirya Kusuma Duarsa. Supervision: Gede Wirya Kusuma Duarsa, Anak Agung Gede Oka, Kadek Budi Santosa, I Wayan Yudiana, Pande Made Wisnu Tirtayasa.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgement

The authors thank the Medical Record Staff of Sanglah General Hospital for providing the data.

References

[1] Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol 2017;4:148–51.
[2] Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005;173:1256–61.
[3] Mochtar CA, Umbas R, Soebadi DM, Purnomo BB, Widjanarko S, Tarmono, et al. Panduan penatalaksanaan klinis pembesaran prostat jinak (benign prostatic hyperplasia/BPH). 2nd ed. Jakarta: Ikatlan Ahli Urologi Indonesia; 2015. p. 1–27.
[4] Duarsa GWK, Lesmana R, Mahadewa TG. High serum prostate specific antigen as a risk factor for moderate-severe prostate inflammation in patient with benign prostatic hyperplasia. Bali Med J 2016;4:148–51.
[5] Chen Z, Miao L, Gao X, Wang G, Xu Y. Effect of obesity and hyperglycemia on benign prostate hyperplasia in elderly patients with newly diagnosed type 2 diabetes. Int J Clin Exp Med 2015;8:11289–94.
[6] Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urol Times 2006;68:804–9.
[7] Bosch J, Tilling K, Bohnen A, Bangma C, Donovan J. Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: prediction of future prostate volume in individual men. Prostate 2007;67:1816–24.
[8] Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Prostate volume changes over time: results from
the Baltimore longitudinal study of aging. J Urol 2009;182:1458–62.

[9] Schaeffer AJ. Infections of the urinary tract. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-walsh urology tenth edition. Philadelphia: Elsevier-Saunders; 2012. p257–326.

[10] Heyns C. Urinary tract infection associated with conditions causing urinary tract obstruction and stasis, excluding ureolithiasis and neuropathic bladder. World J Urol 2012;30:77–83.

[11] Wang S, Mao Q, Lin Y, Wu J, Wang X, Zheng X, et al. Body mass index and risk of BPH: a meta-analysis. Prostate Cancer Prostatis Dis 2012;15:265.

[12] Lee SH, Kim JC, Lee JY, Kim JH, Oh CY, Lee SW, et al. Effects of obesity on lower urinary tract symptoms in Korean BPH patients. Asian J Androl 2009;11:663–8.

[13] Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep 2010;5:212–8.

[14] Kim JM, Song PH, Kim HT, Moon KH. Effect of obesity on prostate-specific antigen, prostate volume, and International Prostate Symptom Score in patients with benign prostatic hyperplasia. Korean J Urol 2011;52:401–5.

[15] Dahlle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168:599–604.

[16] Kok ET, Schouten BW, Bohnen NM, Groeneveld FP, Thomas S, Bosch JR. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J Urol 2009;181:710–6.

[17] Wong SY, Woo J, Leung JC, Leung PC. Depressive symptoms and lifestyle factors as risk factors of lower urinary tract symptoms in Southern Chinese men: a prospective study. Aging Male 2010;13:113–9.

[18] Pelton K, Di Vizio D, Insabato L, Schaffner CP, Freeman MR, Solomon KR. Ezetimibe reduces enlarged prostate in an animal model of benign prostatic hyperplasia. J Urol 2010;184:1555–9.

[19] Lekili M, Muezzinoglu T, Uyanik BS, Buyuksu C. Serum lipid levels in benign prostatic hyperplasia. World J Urol 2006;24:210–3.

[20] Hautanen A. Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes 2000;24:564. https://doi.org/10.1038/sj.ijo.0801281.

[21] Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urol Times 2006;68:1198–205.

[22] Zucchetto A, Tavani A, Dal Maso L, Gallus S, Negri E, Talanini R, et al. History of weight and obesity through life and risk of benign prostatic hyperplasia. Int J Obes 2005;29:798–803.

[23] Bourke J, Griffin J. Diabetes mellitus in patients with benign prostatic hyperplasia. Br Med J 1968;4:492–3.

[24] SAFarinejad MR. Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older. Int Urol Nephrol 2008;40:921–31.

[25] Vikram A, Tripathi D, Ramarao P, Jena G. Intervention of D-glucose ameliorates the toxicity of streptozotocin in accessory sex organs of rat. Toxicol Appl Pharmacol 2008;226:84–93.

[26] Keda K, Wada Y, Foster HE, Wang Z, Weiss RM, Latifpour J. Experimental diabetes-induced regression of the rat prostate is associated with an increased expression of transforming growth factor-β. J Urol 2000;164:180–5.

[27] Haffner S. Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: epidemiological and clinical correlation. Int J Obes 2000;24:S56–8. https://doi.org/10.1038/sjijo.0801279.

[28] Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151–8.

[29] Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes 2005;29:310–6.

[30] Sarma AV, Parsons JK, McVary K, Wei JT. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms—what do we know? J Urol 2009;182:32–7.

[31] Sarma AV, Burke JP, Jacobson DJ, McGree ME, Sawyer JS, Girman CJ, et al. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men. Diabetes Care 2008;31:476–82.

[32] Burke JP, Jacobson DJ, McGree ME, Roberts RO, Girman CJ, Lieber MW, et al. Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota. Urol Times 2006;67:22–5.

[33] Rastrelli G, Vignozzi L, Corona G, Maggi M. Testosterone and benign prostatic hyperplasia. Sex Med Rev 2019;7:259–71.

[34] Schenck JM, Krishal AR, Neuhouser ML, Tangen CM, White E, Lin DW, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2010;171:571–82.

[35] Robert G, Descazeaud A, Allory Y, Vacherot F, Taille ADLA. Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol Suppl 2009;8:839886.

[36] Yalcinkaya FR, Gokcei A, Davarci M, Guven EO, Inci M, Karta S. The impact of NIH-IV prostateitis on early post-operative outcomes of transurethral resection of the prostate in patients with symptomatic benign prostate hyperplasia. Turkish J Med Sci 2011;41:515–9.

[37] Wang X, Lin WJ, Izumi K, Jiang Q, Lai KP, Xu D, et al. Increased infiltrated macrophages in benign prostatic hyperplasia (BPH) role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation. J Biol 2012;287:1837685.

[38] Mazzaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013;112:432–41.

[39] Duarsa GW, Oka AA, Malawian S, Soebadi DM, Astawa P, Oka AA, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013;112:432–41.

[40] Schauer IG, Rowley DR. The functional role of reactive stroma in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013;112:432–41.

[41] van der Sluis TM, Vis AN, van Moorselaar RJA, Bui HN, Zucchetto A, Tavani A, Dal Maso L, Gallus S, Negri E, et al. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer. BJU Int 2012;109:176–82.

[42] van der Sluis TM, Vis AN, van Moorselaar RJA, Bui HN, Blankensteijn MA, Meuleman EJ, et al. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer. BJU Int 2012;109:176–82.
[44] Dias JP, Melvin D, Shardell M, Ferrucci L, Chia CW, Gharib M, et al. Effects of transdermal testosterone gel or an aromatase inhibitor on prostate volume in older men. J Clin Endocrinol Metab 2016;101:1865–71.

[45] Dell’Atti L, Galosi AB. The role of the serum testosterone levels as a predictor of prostate cancer in patients with atypical small acinar proliferation at the first prostate biopsy. Asian J Androl 2018;20:15–8.

[46] Deori R, Das B, Rahman MA. A study of relationship of prostate volume, prostate specific antigen, and age in benign prostatic hyperplasia. Int J Contemp Med Res 2017;4:1582–6.

[47] Putra IBO, Hamid AR, Mochtar CA, Umbas R. Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia. Prostate Int 2016;4:43–8.